Janux Therapeutics, Inc. (JANX)
Market Cap | 3.34B |
Revenue (ttm) | 13.05M |
Net Income (ttm) | -60.54M |
Shares Out | 52.48M |
EPS (ttm) | -1.19 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 36,352 |
Open | 64.00 |
Previous Close | 63.45 |
Day's Range | 62.14 - 64.00 |
52-Week Range | 7.79 - 71.71 |
Beta | 3.29 |
Analysts | Strong Buy |
Price Target | 83.09 (+30.62%) |
Earnings Date | Nov 6, 2024 |
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth ... [Read more]
Financial Performance
In 2023, Janux Therapeutics's revenue was $8.08 million, a decrease of -6.14% compared to the previous year's $8.61 million. Losses were -$58.29 million, -7.56% less than in 2022.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is $83.09, which is an increase of 30.62% from the latest price.
News
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics Announces Proposed Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering.
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
On Monday, Janux Therapeutics, Inc. JANX revealed updated interim clinical data for its JANX007 clinical program.
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment.
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC.
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event.
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA ...
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights.
Janux Therapeutics Announces Updates to Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...
Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy
Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer ...
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights.
Janux Therapeutics (JANX) stock has gone parabolic: what next?
Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above t...
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatme...
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants.
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. Wi...
Janux Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering of Common Stock.
Janux Therapeutics surges as trial data for prostate cancer therapy shows promise
Janux Therapeutics shares more than doubled in value before the bell on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced...
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
SAN DIEGO--(BUSINESS WIRE)---- $JANX--PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors.
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008.
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer.